NCT06616233

Brief Summary

This study will test the impact of remote ischaemic conditioning combined with exercise on myocardial perfusion in patients with or at risk of heart failure

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

April 8, 2024

Completed
6 months until next milestone

First Posted

Study publicly available on registry

September 27, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

September 27, 2024

Status Verified

November 1, 2023

Enrollment Period

1.5 years

First QC Date

November 30, 2023

Last Update Submit

September 23, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Myocardial perfusion reserve

    myocardial perfusion reserve under adenosine stress as assessed by quantitative cardiovascular magnetic resonance (CMR)

    4 weeks

  • Contraction strength in the cuff deflation phase of RIC

    contraction force achieved during cuff deflation phase, measured in Newtons

    1 day

  • Hyperaemic myocardial blood flow

    myocardial blood flow under adenosine stress as assessed by quantitative cardiovascular magnetic resonance (CMR)

    4 weeks

Secondary Outcomes (5)

  • Brachial artery flow mediated dilation

    4 weeks

  • Skeletal muscle strength

    4 weeks

  • Skeletal muscle endurance

    4 weeks

  • Cardiopulmonary exercise test

    4 weeks

  • Brachial artery maximal dilatory capacity

    4 weeks

Study Arms (2)

Remote Ischaemic Conditioning with Exercise

EXPERIMENTAL

Participants will be randomised to receive remote ischaemic conditioning (RIC) with exercise involving a 4-week home-based programme of RIC with exercise . The exercise will involve handgrip exercise during the cuff deflation phase of RIC.

Device: Remote Ischaemic Conditioning with exercise

Remote Ischaemic Conditioning

OTHER

Participants will receive remote ischaemic conditioning (RIC) without exercise involving a 4-week home-based programme of RIC.

Device: Other: Remote Ischaemic Conditioning

Interventions

Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.

Remote Ischaemic Conditioning with Exercise

Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.

Remote Ischaemic Conditioning

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>18 years
  • Ability to provide written consent
  • clinical diagnosis of HFpEF (LVEF ≥50%; symptoms and signs of heart failure \[HF\] caused by a structural and/or functional abnormality, and at least one: elevated natriuretic peptides; ambulatory; BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL or hospitalised; BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL, and objective evidence of cardiogenic pulmonary or systemic congestion) OR stable type 2 diabetes (determined by formal diagnosis in hospital or GP case records with diagnostic oral glucose tolerance test or glycated haemoglobin level ≥6.5%) and with ACC/AHA stage B HF (structural disorder of the heart but no current or previous symptoms of HF) OR confirmed diagnosis of dilated cardiomyopathy

You may not qualify if:

  • Absolute contraindications to MRI or contrast (e.g. severe claustrophobia, pregnancy, ferromagnetic implants, inability to lie flat, severe renal impairment eGFR\<30ml/min/m2)
  • Moderate to severe valvular heart disease
  • Confirmed coronary artery disease (\>50% narrowing in any major epicardial coronary artery on invasive or computed tomography coronary angiography, previous myocardial infarction, previous percutaneous intervention or coronary bypass surgery)
  • Known arterial stenosis of the upper extremity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Glenfield Hospital

Leicester, Leics, LE3 9QP, United Kingdom

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Cardiomyopathy, Dilated

Interventions

Exercise Therapy

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesCardiomegalyHeart DiseasesCardiovascular DiseasesCardiomyopathiesLaminopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

RehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy Modalities

Study Officials

  • Jayanth R Arnold, BMBCh DPhil

    University of Leicester

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jayanth Arnold, BMBCh DPhil

CONTACT

Aaron Wiseman

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Blinded analysis of data
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised trial of the effect of remote ischemic conditioning with or without lower intensity exercise on hyperaemic myocardial blood flow in patients with or at risk of heart failure.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 30, 2023

First Posted

September 27, 2024

Study Start

April 8, 2024

Primary Completion

October 1, 2025

Study Completion

October 1, 2025

Last Updated

September 27, 2024

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

no plan to share IPD

Locations